Weekly Research Analysts’ Ratings Updates for Eli Lilly and Company (LLY)

A number of firms have modified their ratings and price targets on shares of Eli Lilly and Company (NYSE: LLY) recently:

• 2/9/2026 – Eli Lilly and Company had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $1,200.00 to $1,285.00. They now have a “buy” rating on the stock.
• 2/5/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by analysts at Scotiabank. They now have a $1,300.00 price target on the stock.
• 2/5/2026 – Eli Lilly and Company was given a new $1,281.00 price target on by analysts at Truist Financial Corporation.
• 2/5/2026 – Eli Lilly and Company was given a new $1,260.00 price target on by analysts at The Goldman Sachs Group, Inc..
• 2/5/2026 – Eli Lilly and Company had its price target raised by analysts at Wells Fargo & Company from $1,200.00 to $1,280.00. They now have an “overweight” rating on the stock.
• 2/5/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $1,300.00 price target on the stock.
• 2/5/2026 – Eli Lilly and Company had its price target raised by analysts at Leerink Partners from $1,234.00 to $1,296.00. They now have an “outperform” rating on the stock.
• 2/5/2026 – Eli Lilly and Company had its price target raised by analysts at JPMorgan Chase & Co. from $1,150.00 to $1,300.00. They now have an “overweight” rating on the stock.
• 2/5/2026 – Eli Lilly and Company had its price target raised by analysts at Cantor Fitzgerald from $985.00 to $1,205.00. They now have an “overweight” rating on the stock.
• 2/5/2026 – Eli Lilly and Company had its price target raised by analysts at Morgan Stanley from $1,290.00 to $1,313.00. They now have an “overweight” rating on the stock.
• 2/4/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
• 2/2/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 1/31/2026 – Eli Lilly and Company was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 1/30/2026 – Eli Lilly and Company was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 1/29/2026 – Eli Lilly and Company had its price target raised by analysts at TD Cowen from $960.00 to $1,250.00. They now have a “buy” rating on the stock.
• 1/26/2026 – Eli Lilly and Company had its price target raised by analysts at Rothschild & Co Redburn from $775.00 to $830.00. They now have a “neutral” rating on the stock.
• 1/20/2026 – Eli Lilly and Company had its price target lowered by analysts at Guggenheim from $1,163.00 to $1,161.00. They now have a “buy” rating on the stock.
• 1/14/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by analysts at BMO Capital Markets.
• 1/8/2026 – Eli Lilly and Company had its price target raised by analysts at Jefferies Financial Group Inc. from $976.00 to $1,300.00. They now have a “buy” rating on the stock.
• 1/6/2026 – Eli Lilly and Company is now covered by analysts at UBS Group AG. They set a “buy” rating and a $1,250.00 price target on the stock.
• 1/5/2026 – Eli Lilly and Company was given a new $1,234.00 price target on by analysts at Leerink Partners.
• 1/1/2026 – Eli Lilly and Company was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 12/22/2025 – Eli Lilly and Company had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/19/2025 – Eli Lilly and Company had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein.
• 12/18/2025 – Eli Lilly and Company had its “outperform” rating reaffirmed by analysts at Leerink Partners.
• 12/18/2025 – Eli Lilly and Company had its “neutral” rating reaffirmed by analysts at UBS Group AG.
• 12/17/2025 – Eli Lilly and Company had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $1,000.00 to $1,200.00. They now have a “buy” rating on the stock.
• 12/16/2025 – Eli Lilly and Company was given a new $1,230.00 price target on by analysts at Daiwa Securities Group Inc.. They now have a “buy” rating on the stock.
• 12/16/2025 – Eli Lilly and Company was upgraded by analysts at Daiwa Securities Group Inc. from a “hold” rating to a “strong-buy” rating.
• 12/15/2025 – Eli Lilly and Company had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Eli Lilly and Company had its price target raised by analysts at The Goldman Sachs Group, Inc. from $951.00 to $1,145.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Eli Lilly and Company had its price target lowered by analysts at Bank of America Corporation from $1,286.00 to $1,268.00. They now have a “buy” rating on the stock.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 26.14%.

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.